Key result
This review summarizes available information and provides general guidance for risk assessment regarding the periprocedural management of platelet-directed pharmacotherapy in patients with coronary artery disease.
Provides a summary of available information and general guidance for risk assessment regarding the periprocedural management of antiplatelet therapy in CAD patients undergoing elective GI endoscopy.
The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
No takes yet. Share an insight, caveat, or question.
Becker et al. (2009) conducted a review in Atherosclerotic coronary heart disease undergoing elective endoscopic gastrointestinal procedures. Periprocedural management of platelet-directed pharmacotherapy was evaluated. This review summarizes available information and provides general guidance for risk assessment regarding the periprocedural management of platelet-directed pharmacotherapy in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: